Comparative Pharmacology
Head-to-head clinical analysis: BRETYLIUM TOSYLATE IN DEXTROSE 5 versus SOTALOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETYLIUM TOSYLATE IN DEXTROSE 5 versus SOTALOL HYDROCHLORIDE.
BRETYLIUM TOSYLATE IN DEXTROSE 5% vs SOTALOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bretylium tosylate is an antiarrhythmic agent that prolongs the action potential duration and refractory period in cardiac tissue. It initially causes release of norepinephrine from sympathetic nerve endings, followed by inhibition of norepinephrine release. It has class III antiarrhythmic properties and also exhibits adrenergic blockade.
Sotalol is a non-selective beta-adrenergic receptor antagonist (beta-blocker) with additional class III antiarrhythmic activity (prolongation of cardiac action potential duration via blockade of potassium channels). It decreases heart rate, myocardial contractility, and AV conduction velocity, and increases ventricular refractoriness.
Intravenous: 5-10 mg/kg infused over 10-30 minutes, may repeat at 30-minute intervals up to a total of 30 mg/kg; maintenance: 1-2 mg/min as continuous IV infusion or 5-10 mg/kg every 6 hours by intermittent infusion. Intramuscular: 5-10 mg/kg undiluted, repeat every 1-2 hours as needed.
Initial: 80 mg orally twice daily; may increase every 3 days to 160-320 mg/day, maximum 640 mg/day (for life-threatening arrhythmias). Also available as 80 mg intravenous over 20 minutes (1.5 mg/kg) for acute management.
None Documented
None Documented
Terminal elimination half-life is approximately 7-11 hours in patients with normal renal function, but can be prolonged to >24 hours in renal impairment or anuria, necessitating dose adjustment.
Terminal elimination half-life: 10-20 hours in normal renal function; prolonged in renal impairment (up to 40 hours), requiring dose adjustment.
Primarily excreted unchanged by the kidneys via glomerular filtration and tubular secretion; >70% of an administered dose recovered in urine within 24 hours; negligible biliary/fecal elimination.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <20%.
Category C
Category A/B
Antiarrhythmic (Class III)
Antiarrhythmic (Class III)